Supplementary Figure 4 from Nuclear–Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis
Dongqing Yan(Sun Yat-sen University), Michael W. Deininger(Versiti Blood Center of Wisconsin), Brayden J. Halverson(Huntsman Cancer Institute), Kevin C. Gantz(Huntsman Cancer Institute), Rodney R. Miles(Inserm), Hein Than(Singapore General Hospital), Phillip M. Clair(University of Utah), Mohamed E. Salama(The University of Texas at San Antonio Health Science Center), Josef T. Prchal(Huntsman Cancer Institute), Srinivas K. Tantravahi(University of Utah), Sharon Shacham(Roche (Switzerland)), Clinton C. Mason(National Institute of Diabetes and Digestive and Kidney Diseases), Anna V. Senina(Astex Pharmaceuticals), Erkan Baloglu(ProterixBio (United States)), Anna M. Eiring(The University of Texas at El Paso), Jonathan M. Ahmann(Huntsman Cancer Institute), Hannah M. Redwine(Huntsman Cancer Institute), Kenneth M. Boucher(University of Utah), Ami B. Patel(University of Utah), William L. Heaton(University of Utah), Sabina Świerczek(University of Utah), Qiang Wang(Jiangsu University), Todd W. Kelley(University Hospitals Cleveland Medical Center), Anthony D. Pomicter(University of Utah), Thomas O’Hare(University of Utah), Jamshid S. Khorashad(Royal Marsden NHS Foundation Trust)
Cited by 0
Related Papers
MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition
|Cancer Cell|2017|619
Spectrum of Epithelial Neoplasms in End-Stage Renal Disease
|The American Journal of Surgical Pathology|2006|484
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464
A genetic mechanism for Tibetan high-altitude adaptation
|Nature Genetics|2014|441